1-B-D arabinofuranosyl cytosine and all-trans retinoic acid in combination accelerates and increases monocyte differentiation of myeloid leukemic cells

Leuk Res. 1986;10(6):631-6. doi: 10.1016/0145-2126(86)90265-1.

Abstract

The effect of the combination of two different agents on myeloid differentiation was studied. Human promyelocytic cells (HL-60) and monoblast-like cells (U-937) were treated with 1-B-D arabinofuranosyl cytosine (Ara-C) alone, or in combination with retinoic acid (trans-RA). The known dual potentiality of HL-60 promyelocytes was confirmed by their ability to mature into granulocytes following induction by retinoic acid and into monocyte-like cells following treatment with 1-B-D arabinofuranosyl cytosine. The U-937 cell line differentiated to monocyte-like cells with either of the two drugs. The differentiation induced by Ara-C involved an irreversible step after 24-h incubation with the drug, was concentration dependent, and far more superior on U-937 cells than on HL-60 cells. The outcome of these two cell lines after treatment with both Ara-C and trans-RA was also different: this combination maintained the monocyte differentiation in the HL-60 cell line, and resulted in a higher sensitivity of U-937 cells to Ara-C, as indicated by a cell response to low Ara-C concentrations and a more rapid expression of monocyte specific properties.

MeSH terms

  • Antibodies, Monoclonal
  • Cell Differentiation / drug effects*
  • Cell Line
  • Cells, Cultured
  • Cytarabine / administration & dosage*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Synergism
  • Humans
  • In Vitro Techniques
  • Isomerism
  • Leukemia, Myeloid, Acute / pathology*
  • Nitroblue Tetrazolium
  • Tretinoin / administration & dosage*

Substances

  • Antibodies, Monoclonal
  • Cytarabine
  • Nitroblue Tetrazolium
  • Tretinoin